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Abstract
Background: Children aged between one and five years are particularly vulnerable to disease caused by
soil-transmitted helminths (STH). Periodic deworming has been shown to improve growth, micronutrient
status (iron and vitamin A), and motor and language development in preschool children and justifies the
inclusion of this age group in deworming programmes. Our objectives were to describe the prevalence
and intensity of STH infection and to investigate the effectiveness of repeated four-monthly albendazole
treatments on STH infection in children aged one to four years.
Methods: The study was carried out in four semi-urban villages situated near Ile-Ife, Osun State, Nigeria.
The study was a double-blind placebo-controlled randomised trial. Children aged one to four years were
randomly assigned to receive either albendazole or placebo every four months for 12 months with a
follow-up at 14 months.
Results: The results presented here revealed that 50% of the preschool children in these semi-urban
communities were infected by one or more helminths, the most prevalent STH being Ascaris lumbricoides
(47.6%). Our study demonstrated that repeated four-monthly anthelminthic treatments with albendazole
were successful in reducing prevalence and intensity of A. lumbricoides infections. At the end of the follow-
up period, 12% and 43% of the children were infected with A. lumbricoides and mean epg was 117 (S.E. 50)
and 1740 (S.E. 291) in the treatment and placebo groups respectively compared to 45% and 45% of the
children being infected with Ascaris and mean epg being 1095 (S.E. 237) and 1126 (S.E. 182) in the treatment
and placebo group respectively at baseline.
Conclusion: Results from this study show that the moderate prevalence and low intensity of STH
infection in these preschool children necessitates systematic treatment of the children in child health
programmes.
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Background
Soil-transmitted helminths (STH) are included in the list
of the world's neglected tropical diseases [1]. The STHs
include the roundworm Ascaris lumbricoides, the whip-
worm Trichuris trichiura, the hookworms, Ancylostoma duo-
denale and Necator americanus, and Strongyloides stercoralis.
The global burden of disease caused by these intestinal
nematodes is an estimated 22.1 million disability
adjusted life years (DALYs) lost to hookworm, 10.5 mil-
lion to A. lumbricoides, 6.4 million to T. trichiura, giving a
combined total of 39 million life years [2]. The wider
community has recognised the importance of STHs
acknowledging that their disease burden is as great as
those of tuberculosis (34.7 million DALYs) or malaria
(46.5 million DALYs) [3].
Growth stunting, iron-deficiency anaemia, rectal prolapse
and chronic dysentery are features of STH infections; these
parasitic infections can also adversely affect cognitive
development in childhood [4]. The morbidity due to STH
infections is greatest in school-age children who typically
have the highest intensity of helminth infections [5-10].
In 2001, the World Health Assembly passed a resolution
urging member states to control the morbidity of STH
infections through large-scale use of anthelminthic drugs
for school-aged children in less developed countries [11].
Children aged between one and five years are particularly
vulnerable to disease caused by STH infections [4,12,13].
Although, children of these age groups are less likely to
harbour heavy infections, their worm burdens are housed
in smaller bodies, and therefore they are at a higher risk of
anaemia and wasting malnutrition [14].
Preschool children, defined as aged less than five years,
make up between 10%–20% of the two billion people
worldwide who are infected with STHs; 21 million pre-
school children are infected with hookworm, 122 million
are infected with A. lumbricoides and 86 million are
infected with T. trichiura [15]. Periodic deworming has
been shown to improve growth, micronutrient status
(iron and vitamin A), and motor and language develop-
ment in preschool children and justifies the inclusion of
this age group in these deworming programmes [16]. Fur-
ther assessment of the drug efficacy of anthelminthic
drugs in this age group is needed [16] with particular
attention to the optimal dosage of anthelminthics in
order to maximise the efficacy and minimise the risks of
these drugs in children aged less than 24 months [17].
This study was undertaken as part of a larger study inves-
tigating the relationship between STHs and malaria in
preschool children. Our objectives were to describe the
prevalence and intensity of STH infection and to investi-
gate the effectiveness of repeated four-monthly albenda-
zole treatments on STH infection in children aged one to
four years.
Methods
Study area and participants
The study was carried out between May 16, 2006, and
August 22, 2007, in four semi-urban villages, Akinlalu,
Ipetumodu, Moro and Edunabon, situated near Ile-Ife,
Osun State, Nigeria. The climate is characterised by a high
uniform temperature, moderate to heavy seasonal rain-
fall, and high relative humidity. The dry season extends
from November to March while the rainy season occurs
from April to October [18]. Annual rainfall in the region
ranges from 1000 to 4000 mm [18]. The average maxi-
mum and minimum daily temperatures are 32°C and
20°C respectively and the vegetation is rainforest[18].
The inhabitants of these communities are a mixture of
people from different ethnic groups, although the major-
ity are Yoruba-speaking. Houses in the villages are pre-
dominately built of concrete floors and walls and roofed
with corrugated galvanised iron sheets. There is no organ-
ised sewage disposal system and refuse and human faeces
are dumped in the bush or burned. The main source of
water is from shared community taps and/or wells located
in each village. Health care is provided in health centers
located in each village, these are inadequately equipped
and lack essential supplies and qualified staff. STHs are
endemic in this region [9,18].
Meetings were held with the Obas (traditional head of a
Yoruba village), Ife North Local Government and inhabit-
ants of the village in May 2006 to explain the aims of the
study. The Obas made a call for children aged 12–60
months to attend temporary clinics for assessments on
specified dates. The assessments took place in the town
hall at the Oba's palace, which was located at the centre of
each village. Participation in the study was voluntary. The
study was explained to each mother on the day of the
assessment and they were asked to sign or finger print the
consent form to enroll their child. The consent forms were
provided in English and Yoruba. Each child was given an
identification card with an ID number and was requested
to present this card on all subsequent visits. Mothers were
interviewed using a questionnaire by a trained fieldworker
who collected data on age and gender of the child and
socio-economic status. The study protocol was approved
by the Ethics and Research Committee, Obafemi
Awolowo University Teaching Hospitals' Complex, Ile-Ife,
Nigeria.
Study design
The study was a double-blind placebo-controlled ran-
domised trial. Children aged 12–59 months were ran-
domly assigned to receive either albendazole or placeboBMC Infectious Diseases 2009, 9:20 http://www.biomedcentral.com/1471-2334/9/20
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every four months for 12 months with a follow-up at 14
months. Albendazole and placebo tablets were identical
and manufactured by GlaxoSmithKline. All eligible chil-
dren received either treatment or placebo tablets on four
occasions. Children were directly supervised to ensure
that they took their tablet(s). Children aged one year
received 200 mg of albendazole (1 tablet) and children
aged ≥ 2 years received 400 mg (2 tablets) of albendazole
[17]. Mothers were asked to inform the fieldworkers if
their children had any adverse reactions to the anthelmin-
thic drugs. Children in the placebo group were treated
with albendazole at the end of the study. This trial is
reported in accordance with the CONSORT guide-lines for
randomised studies [19].
Prior to commencing the trial SOA placed the albendazole
and placebo tablets in containers labelled either A or B.
The treatment coordinator, SFM, oversaw the allocation of
treatments to the children. During the first assessment
each alternate child was assigned tablet B on returning a
stool sample. Experienced physicians (TCA and Dr. OK
Onabajo) enrolled all participants, measured all study
endpoints, and were kept masked to treatment allocation
of children. Field workers involved in data collection and
mothers of participating children were also masked to the
treatment allocation.
Procedures
The primary outcome was prevalence and intensity of
STHs. Children were screened for STHs at 0, 4, 8, 12, and
14 months. Stool samples were obtained before treatment
was provided and stools were processed by formol-ether
concentration [20]. STH infection was defined by the pres-
ence of eggs of A. lumbricoides, T. trichiura, hookworm or
Schistosoma haematobium in the stool sample. An indirect
measure of helminth intensity was obtained by counting
eggs per gram of faeces (epg). Helminth intensity was cat-
egorised into light and moderate infections [11]. To main-
tain consistency all stool samples were examined by PK.
All children received 10 ml of multivitamins (over two
days) as an incentive at each time point. Each 5 ml of mul-
tivitamin contained: Vitamin A 3000 IU, Vitamin B2 2.0
mg, Nicotinamide 15.0 mg, Vitamin B1 1.5 mg, Vitamin
B6 2.0 mg, Vitamin D2 400 IU, D panthenol 1.0 mg.
Statistical analysis
Estimation of sample size was based on the percentage
change in malaria attacks for patients with Ascaris treated
with albendazole. In a pilot study patients infected with
helminths had more malaria attacks (11.1%) than
patients who were not infected (4%) (P. Kirwan unpub-
lished data). To detect a 7.1% reduction in malaria
attacks, a study with 90% power and a significance level of
P < 0.05 would need a sample size of 572 children. In the
pilot study 42% of study participants did not return faecal
samples. To account for this lack of compliance with fae-
cal samples and a loss to follow-up (30%) the sample size
was adjusted to 1055. The data on epg were assessed for
normality visually and statistically. Epg values did not
conform to a normal distribution and therefore the epg
data were log transformed (epg +1) for the purposes of
statistical analysis. Log transforming the epg data normal-
ised the distribution of the values. All statistics were car-
ried out in SPSS 14. Socio-economic status (SES) was
calculated as a score based on the number of key posses-
sions in a person's household.
A chi-square analysis was used to test the difference in the
prevalence of Ascaris  among age groups, villages and
between the sexes at baseline. The influence of factors
(age, village and sex) on epg were analysed by analysis of
variance (ANOVA), using 3-way ANOVAs. In some cases
least squares difference (LSD) post-hoc tests were applied
to tease out the major sources of variation within factors.
Children that were lost to follow-up and children that
were analysed were compared on the basis of their base-
line characteristics, age, sex, village and SES and parasitic
infections. A similar comparison was also undertaken to
compare the characteristics of children in the treatment
and placebo groups at inclusion into the study. Chi-
square analysis was used to test proportions or Fisher's
exact test when more than 20% of the cells had expected
counts of less than five and 2-sample t-tests to test epg and
SES.
The prevalence of A. lumbricoides was analysed using a lin-
ear mixed effects model using a logit function with the
assumption that the observed data were binomially dis-
tributed. The analyses were run in R v2.6.2 [21] using the
function lmer contained in the package lme4. A random
effect for each individual was included to take account of
the nested data structure (multiple observations made on
each child). The effect of treatment (treatment or placebo)
and age were included as fixed factors with time as a cov-
ariate. An interaction term between time and treatment
was also included in the model. Parameter effects in the
mixed effects model are presented as log(odds). In order to
determine the proportional change in odds in the figures,
we calculate exp(log(odds)).
Mean epg was measured over five time points from the
same individuals. Since the data was not independent, it
was analysed by repeated measures rmANOVA (General
Linear Model) with the different time points as a within-
subject factor. Group, age and sex were chosen as the
between-subject factors; these factors were entered into
the model if they were significant in the 3-way ANOVA.
Since the data did not meet the requirements of sphericity,BMC Infectious Diseases 2009, 9:20 http://www.biomedcentral.com/1471-2334/9/20
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the Huynh-Feldt adjustment to the degrees of freedom
was used to interpret the output on the side of caution.
Results
Figure 1 shows the trial profile. 1228 subjects were ran-
domised into this study; 625 to albendazole and 603 to
placebo. 31.6% of the eligible children complied with all
the follow-up assessments.
Prevalence and intensity of helminth infections at baseline
50.5% children were infected with any helminth at base-
line (Table 1). A. lumbricoides was the predominant STH
infection with 47.6% of the children being parasitised
(Table 1). 3.7% of the children were infected with T.
trichiura, 4.3% with hookworm and 1.1% with S. haema-
tobium (detected in stool samples). The majority of Ascaris
infections were of light intensity (85.9%); 14.1% of the
children had moderate infections. All T. trichiura and
hookworm infections were of light intensity.
The prevalence of Ascaris increased with age being 38.2%
in children aged one year and 56.8% in children aged
three years and this was statistically significantly (Table 1;
χ2 = 30.563, df = 3, P < 0.001). There was no statistically
significant difference in the prevalence of A. lumbricoides
between villages and sexes. Older children aged two
(1386 ± S.E. 190), three (1636 ± S.E. 218) and four (1059
± S.E. 166) years had a higher mean epg for A. lumbricoides
than younger children aged one year (504 ± S.E. 67) (3-
way ANOVA with village, age and sex as factors, model
R2
adj = 0.048, main effect of age, F3, 1196 = 16.333, P <
0.001). Females had a higher epg (1222 ± S.E.116) than
males (941 ± S.E.107)(main effect of sex, F1, 1196 = 6.455,
P = 0.011). There was no statistically significant difference
in mean epg between villages. The LSD post-hoc analysis
confirmed that mean epg was significantly different
between children aged one year and two (P < 0.001), three
(P < 0.001) and four years (P = 0.013); children aged two
and four years (P = 0.008) and children aged three and
four years (P = 0.003).
Trial Profile Figure 1
Trial Profile.
 
  1451 individuals assessed for eligibility 
 
 
 
 
223 individuals excluded 
12 did not complete the assessments 
   1 passed worms 
   3 severe anaemia 
   1 severe malaria 
   5 died (reason unknown) 
   201 did not submit a stool sample 
1228 individuals randomised 
625 individuals allocated to albendazole  603 individuals allocated to placebo 
431 did not complete 14 months follow-
up 
409 did not complete 14 months follow-
up 
194 individuals for stool analysis  194 individuals for stool analysis BMC Infectious Diseases 2009, 9:20 http://www.biomedcentral.com/1471-2334/9/20
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No adverse events were recorded concerning albendazole
treatment. The baseline characteristics were similar for
children who were analysed and who were lost to follow-
up (Table 2). The randomised design resulted in a similar
distribution of baseline variables between the treatment
and placebo groups (Table 2).
Effect of treatment on A. lumbricoides infection
The prevalence of A. lumbricoides in the placebo group
remained persistently high throughout the follow-up
when compared to the treatment group (Figure 2A). It
took three rounds of anthelminthic treatment before the
prevalence of A. lumbricoides dropped in the treatment
group. There was a significant interaction between treat-
ment group and time in the linear mixed effects model
analysis (P < 0.001; Table 3). At the beginning of the trial,
the odds of being infected with A. lumbricoides was slightly
larger in the treatment group, but not significantly so.
However, as time progressed, the odds of being infected
decreased in the treatment group (Table 3; Figure 3). In
contrast, the placebo group had no significant relation-
ship with time and had a constant odds of infection (Fig-
ure 3). Prevalence peaked at 8 months for both the
treatment and placebo groups. By the end of the follow-
up period (14 months), 12.9% of the children were
infected with A. lumbricoides in the treatment group, while
43.8% were infected in the placebo group. The prevalence
of A. lumbricoides was comparable for all age groups and
demonstrated a similar pattern within the treatment and
placebo groups over the study period (Figure 4A). The
group*age interaction was not significant (P > 0.1) in the
linear mixed effects model and was dropped from the
final model.
The epg varied significantly over time (Figure 2B;
rmANOVA, main effect of time (within subject analysis)
F3.7,1439.7 = 21.93, P < 0.001). Unlike prevalence, when
compared to the placebo group mean epg in the treatment
group dropped after one round of anthelminthic treat-
ment, rising slightly at 8 months but remaining at low lev-
els throughout the follow-up period (Figure 2B). The
mean epg in the placebo group increased after 4 months
and stabilised (time*group interaction (within subject
analysis) F3.7,1439.7 = 18.57, P < 0.001). The mean epg
dropped by 89.3% in the treatment group from 1095 (S.E.
237) at baseline to 117 (S.E. 50) at 14 months, whereas
the mean epg increased by 54.5% in the placebo group
from 1126 (S.E. 182) at baseline to 1740 (S.E. 291) at 14
months (main effect of group (between subject analysis)
F1,382 = 46.42, P < 0.001). At baseline, the number of mod-
erate infections in the treatment and placebo group was
12 (6.2%) and 15 (7.7%) respectively. By the end of the
follow-up the number of moderate infections dropped to
2 (1%) in the treatment group and increased to 23
(11.9%) in the placebo group.
The two- and three-way interactions with age and sex were
non-significant (P > 0.1) and were therefore dropped
from the final rmANOVA model. The pattern of epg across
time was similar for the age groups (Figure 4B; time*age
Table 1: Baseline patterns of STH and S. haematobium infections in children aged 1–4 years.
Age (years)
Overall
(N = 1228)
1
(N = 422)
2
(N = 288)
3
(N = 280)
4
(N = 238)
Any helminth
No. infected 620 (50.5%) a 167 (39.6%) 161 (55.9%) 172 (61.4%) 120 (50.4%)
A. lumbricoides
No. Infected 585 (47.6%) 161 (38.2%) 157 (54.5%) 159 (56.8%) 108 (45.4%)
Mean epg ± SE 1077 ± 78 504 ± 67 1386 ± 190 1636 ± 218 1059 ± 166
T. trichiura
No. Infected 46 (3.7%) 6 (1.4%) 12 (4.2%) 15 (5.4%) 13 (5.5%)
Mean epg ± SE 4 ± 2 1 ± 1 4 ± 2 2 ± 1 12 ± 11
Hookworm
No. Infected 53 (4.3%) 8 (1.9%) 10 (3.5%) 19 (6.8%) 16 (6.7%)
Mean epg ± SE 4 ± 1 2 ± 1 3 ± 2 7 ± 4 7 ± 3
S. haematobium
No. Infected 14 (1.1%) 3 (0.7%) 1 (0.3%) 6 (2.1%) 4 (1.7%)
Mean epg ± SEb 0.03 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 0.05 ± 0.02 0.05 ± 0.02
a % prevalence
b The maximum number of eggs detected in an individual was 6BMC Infectious Diseases 2009, 9:20 http://www.biomedcentral.com/1471-2334/9/20
Page 6 of 13
(page number not for citation purposes)
interaction (within subject analysis) F11.3,1439.7 = 2.11, P =
0.211). In the treatment group, epg decreased from base-
line for children aged two to four years, increasing at 8
months and decreasing thereafter for all age groups. In
comparison, in the placebo group the epg for children
aged two to four years remained high at 4 months,
increasing for all age groups at 8 months and continued to
be high throughout the study period. The pattern of epg
was similar for the age groups within the placebo and
treatment groups over time, which was verified by the
non-significant time*group*age interaction which was
dropped from the final rmANOVA model. There was no
significant main effect of age thus the age groups did not
vary in their epg (Figure 4B; main effect of age (between
subject analysis) F3,382 = 1.549, P = 0.202).
The pattern of epg across time was similar for the sexes
(Figures 5 and 6; time*sex interaction (within subject
analysis) F3.7,1439.7 = 1.027, P = 0.389). For females the
mean epg decreases after 4 months in the treatment group
and remains at low levels throughout the follow-up
period when compared to the placebo group where mean
epg remains higher with a sharp increase at 4 months (Fig-
ure 5). In contrast to females, although mean epg for
males decreases after 4 months in the treatment group, the
mean epg for both treatment and placebo groups does not
diverge until 8 months i.e. after three rounds of treat-
ments. Despite this, the pattern of epg was similar for the
sexes within the treatment and placebo groups over time,
this was demonstrated by the non-significant interaction
between time*group*sex which was dropped from the
final rmANOVA model. There was a significant main
effect of sex so the sexes varied in their epg (Figures 5 and
6; main effect of sex (between subject analysis) F1,382 =
4.606, P < 0.032).
Discussion
The results presented here revealed that 50% of the pre-
school children in these semi-urban communities are
infected by one or more helminths, the most prevalent
Table 2: Baseline characteristics for individuals that were lost to follow-up and individuals that were analysed, and individuals in the 
treatment and placebo group
Individuals lost to follow-up
(N = 840)
Individuals analysed
(N = 388)
PT r e a t m e n t  G r o u p
(N = 194)
Placebo Group
(N = 194)
P
Characteristic
Age (months)
12–23 287 (34.2%) 135 (34.8%) 0.336* 72 (37.1%) 63 (32.5%) 0.374*
24–35 187 (22.3%) 101 (26%) 46 23.7%) 55 (28.4%)
36–47 194 (23.1%) 86 (22.2%) 39 (20.1%) 47 (24.2%)
48–59 172 (20.5%) 66 (17%) 37 (19.1%) 29 (14.9%)
Sex
Male 443 (52.7%) 193 (49.7%) 0.329* 103 (53.1%) 90 (46.4%) 0.187*
Female 397 (47.3%) 195 (50.3%) 91 (46.9%) 104 (53.6%)
Village
Akinlalu 99 (11.8%) 86 (22.2%) 0.588* 43 (22.2%) 43 (22.2%) 0.562*
Ipetumodu 378 (45%) 157 (40.5%) 80 (41.2%) 77 (39.7%)
Moro 160 (19%) 59 (15.2%) 33 (17%) 26 (13.4%)
Edun-abon 203 (24.2%) 86 (22.2%) 38 (19.6%) 48 (24.7%)
Socio-economic status
Mean ± SE 6.49 ± 0.10 6.28 ± 0.06 0.077 6.39 ± 0.13 6.59 ± 0.15 0.324
Parasitic infections
Ascaris lumbricoides 409 (48.7%) 176 (45.4%) 0.277* 88 (45.4%) 88 (45.4%) 1*
Mean epg ± SE 1060.69 ± 91.70 1111 ± 149.53 0.581 1095.19 ± 237.48 1126.81 ± 182.39 0.777
Trichuris trichiura 34 (4%) 12 (3.1%) 1§ 5 (2.6%) 7 (3.6%) 0.558*
Mean epg ± SE 5.16 ± 3.07 1.70 ± 1.05 0.81 ± 0.47 2.6 ± 2.06
Hookworm 38 (4.5%) 15 (3.9%) 0.598* 5 (2.6%) 10 (5.2%) 0.188*
Mean epg ± SE 4.86 ± 1.47 3.41 ± 1.75 3.56 ± 2.91 3.26 ± 1.97
Schistosoma haematobium 7 (.8%) 7 (1.8%) 0.153§ 3 (1.5%) 4 (2.1%) 1§
Mean epg ± SE 0.02 ± 0.01 0.06 ± 0.02 0.06 ± 0.04 0.06 ± 0.03
* χ2 test
 t-test
§ Fisher's exact testBMC Infectious Diseases 2009, 9:20 http://www.biomedcentral.com/1471-2334/9/20
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STH being A. lumbricoides (47.6%). Our study demon-
strated that repeated four-monthly anthelminthic treat-
ments with albendazole were successful in reducing
prevalence and intensity of A. lumbricoides infections in
preschool children.
The study may have some potential limitations that need
to be considered when interpreting the findings. Partici-
pants were not randomly selected from the community.
Achieving a random sample of subjects in this field setting
would prove very difficult owing to the widely dispersed
(A) Prevalence rates ± C.I. (A. lumbricoides) and mean epg in treatment and placebo groups during the follow-up period Figure 2
(A) Prevalence rates ± C.I. (A. lumbricoides) and mean epg in treatment and placebo groups during the follow-
up period. (B) Mean epg ± S.E. Treatment group N = 194, Placebo group N = 194.
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nature of these semi-urban communities, and to the
restricted age group being studied. Non-random selection
of subjects is common in epidemiology studies [22,23]
and we believe that the moderate sample size, small age
range and randomised design compensate for the non-
random selection of subjects. 68.4% of children were lost
to follow-up. This high attrition rate may be attributed to
the difficulty in accessing such young children particularly
because they are not of school-going age. School-based
studies provide a better infrastructure and can improve
compliance considerably[24]. Bias caused by such losses
was probably minor because those lost were similar with
respect to important baseline characteristics to those that
were analysed. Epg was used as an indirect measure of
prevalence and intensity of helminth infections. Getting a
true measure of worm burden by expelling the worms
from the gut is very difficult, time-consuming work and is
not feasible for such large-scale studies [25].
The predominant infection in these communities was A.
lumbricoides but lower prevalences of T. trichiura, hook-
worm and S. haematobium were also detected. The preva-
lence of A. lumbricoides increased with age. Maximum
prevalence values for A. lumbricoides are usually observed
when children are 5–10 years old [8]. A previous study in
this region of Nigeria demonstrated the prevalence of A.
lumbricoides to be 88.5% in school children aged 5–15
years [9]. Higher prevalences of Ascaris in studies on chil-
dren aged 0–48 months, have been found in China (80%)
[26], the Philippines (77%) [27], and Sri Lanka (62%)
[28]. Prevalence can vary geographically, lower preva-
lences have been found in children aged 12–48 months in
Zanzibar (41.5%) [29], and children aged 12–47 months
in Nigeria (20.5%) [30].
The majority of Ascaris infections in this study were of
light intensity (85.9%), few children harboured moderate
intensity infections (14.1%). The intensity of infection
increased with age, children aged one year had a lower
mean epg than older children. Children aged 5–15 years
usually have heavier worm burdens [31]. A Nigerian study
that examined strategies for community control of Ascaris,
showed that intensity peaked in children aged 10–14
years (mean epg >20,000) and declined thereafter in older
children and adults (mean epg <10,000) [18]. In the
present study, females had a higher mean epg. Other stud-
ies have also demonstrated that females have heavier
worm burdens [9,32,33] but the cause of this is yet
unknown [8] and could be related to behavioural differ-
ences between males and females. A study in South Afri-
can school children showed that female children were
more likely to be infected with Ascaris  and also had a
higher incidence of soil-eating than males [34].
Four-monthly anthelminthic treatments with albenda-
zole were effective in reducing the prevalence and inten-
sity of A. lumbricoides infections. The rmANOVA analysis
demonstrated that there was a statistically significant dif-
ference in epg between treatment and placebo groups.
Unlike prevalence, the intensity of A. lumbricoides infec-
tions dropped after one round of treatment. Prevalence is
regarded as a relatively insensitive measure of reinfection
because of the aggregated distribution of worms per child
[9]. It has been well documented that marked changes in
intensity may be accompanied by only small changes in
prevalence [35-37]. Furthermore, because of high rates of
reinfection in endemic regions the aim of deworming is
not to reduce prevalence but to reduce morbidity by
decreasing worm burden. Early and regular administra-
tion of single-dose anthelminthic drugs recommended by
WHO reduces the occurance, extent, severity and long-
term consequences of morbidity, and in certain epidemi-
ological conditions contributes to sustained reduction in
transmission [38].
Holland and colleagues [39] proved that four-monthly
anthelminthic treatments with levamisole were better
than six-monthly or one-yearly treatments in reducing
prevalence and intensity of A. lumbricoides infection in
children aged 5–15 years. In the present study, the drop in
prevalence (33%) of Ascaris  between baseline and 14
months was lower than the result demonstrated by Hol-
land et al. [39] for four-monthly treatments where there
was a 54% drop in prevalence by the end of the 13 month
study period. The significant reduction of mean epg
The odds of testing positive for A. lumbricoides as a function  of time for children in the treatment and placebo groups Figure 3
The odds of testing positive for A. lumbricoides as a 
function of time for children in the treatment and 
placebo groups. The placebo group is represented by the 
solid line while the treatment group is represented by the 
dotted line.
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(89%) in the treatment group at the end of the present
study was comparable to the reduction of Ascaris intensity
shown in Holland's study (92.4%; taken from graph). A
study in an urban community in Malaysia showed that
six-monthly treatments with albendazole were effective in
reducing prevalence and intensity of A. lumbricoides infec-
tion [36]. After 12 months (two six-monthly treatments)
the prevalence was reduced by 12% in treated children
aged two to six years (prevalences were taken from a graph
in Chan et al. [36]). This suggests that four-monthly treat-
ments may be better in reducing prevalence of Ascaris in a
similar age group. Mean worm burden was reduced from
3.2 to 1.9 worms in the two to six year olds. Since the anal-
ysis for this present study is based on an indirect measure
of worm burden, epg, it is difficult to compare these
results.
(A) Prevalence rates ± C.I. (A. lumbricoides) and mean epg in treatment and placebo groups for each age group during the fol- low-up period Figure 4
(A) Prevalence rates ± C.I. (A. lumbricoides) and mean epg in treatment and placebo groups for each age group 
during the follow-up period. (B) Mean epg ± S.E.
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A study examining the effect of iron supplementation and
anthelminthic treatment on motor and language develop-
ment of preschool children aged 0.5–5 years in Zanzibar
used repeated three-monthly treatments with mebenda-
zole [29]. After 12 months, prevalence of Ascaris dropped
by 22.3% in the treatment group when compared to the
placebo group. Results from the present study showed
that four-monthly treatments with albendazole reduced
the prevalence of A. lumbricoides by 40.2% in the treat-
ment group after 12 months. Although these studies took
place in different epidemiological settings, the data pre-
sented here suggest that four-monthly treatments with
albendazole were more effective than three-monthly treat-
ments with mebendazole. Three-monthly treatments sig-
nificantly reduced Ascaris intensity [29]; comparing this
data with results presented here is difficult as the intensity
data is presented in geometric means. In contrast to the
work carried out by Stoltzfus et al. [29] a study by Thein-
Hlaing et al. [40] showed that three-monthly anthelmin-
thic treatments were better than four-monthly treatments
at reducing the prevalence of A. lumbricoides; however this
Burmese study was undertaken in children and adults.
The pre-treatment prevalences for all ages and children
less than 15 years were 83.6% and 77.1%, respectively.
After two years of three-monthly treatments the corre-
sponding prevalences fell to 21% and 5% respectively.
In contrast to the results presented here, a study in 117
Bangladeshi preschool children aged 2–6 years showed
that two-monthly anthelminthic treatments were better
Table 3: Linear mixed effects model for the prevalence of A. 
lumbricoides in children aged 1–4 years, with parameter 
estimates (expressed as log-odds) and associated standard error 
of the estimate and p-values.
Coefficient Estimate Std. Error P-value
Intercept -0.02 0.16 0.89
Group
(Treatment)
0.21 0.19 0.274
Age (years)
1 Reference - -
2 0.14 0.17 0.40
3 0.10 0.18 0.59
4 0.04 0.20 0.82
Time 0.01 0.01 0.59
Group(treatment):Time -0.14 0.02 <0.001
Mean epg (± S.E.) (A. lumbricoides) in treated and placebo groups for females during the follow-up period Figure 5
Mean epg (± S.E.) (A. lumbricoides) in treated and placebo groups for females during the follow-up period. Treat-
ment group N = 91, Placebo group N = 104.
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than four-monthly treatments in reducing the prevalence
of A. lumbricoides infections [41]. After one round of treat-
ment, prevalence in the treatment group dropped from
78% to 8% and remained high in the placebo group
increasing from 71% to 74%. After 12 months, the mean
worm burden in the placebo group was 4.1 (maximum:
40) for infected children. An examination of the nine
infected children in the treatment group, yielded five chil-
dren with small immature worms and four children with
one adult worm. Another study in Bangladesh, used two-
monthly repeated treatments with albendazole in 1402
children aged 2–6 years old [42]. When assessing the
effectiveness of anthelminthic treatment on prevalence of
STH infections, a random sub-sample of children were
screened eight months after the initial treatment. Preva-
lence of Ascaris in the treatment group fell by 73% while
prevalence in the placebo group fell by 2%. Similarly, a
study in Madagascar, examining helminth-malaria co-
infections in children and adults used two-monthly treat-
ments with levamisole [43]. Prevalence and intensity of A.
lumbricoides collapsed immediately in the treatment group
after the first round of treatment. Prevalence and intensity
remained high in the placebo group throughout the study
period. While shorter deworming treatment intervals of
two and three months may be better than four-monthly
intervals at reducing prevalence of A. lumbricoides, our
results demonstrate that deworming children at four-
monthly intervals are just as effective in the immediate
reduction of intensity.
In 2002 WHO organised an informal consultation to
assess previous recommendations to avoid the use of
anthelminthic drugs in children less than 24 months [17].
The consultation concluded that although there is little
published information about the use of anthelminthic
drugs in this age group, the data that exists offers no obvi-
ous reason for excluding children of this age group from
treatment. They recommended a 200 mg dose of albenda-
zole instead of 400 mg to be given to children aged less
than 24 months. The present study has demonstrated that
four-monthly treatments were effective in the reducing
the prevalence and intensity of Ascaris infections in chil-
dren aged one year. Future studies should investigate the
efficacy of 200 mg anthelminthic treatments for children
aged one year and determine the optimal dose of albenda-
zole to be used in this age group.
Conclusion
Results from this study show that the moderate prevalence
and low intensity of STH infection in these preschool chil-
Mean epg (± S.E.) (A. lumbricoides) in treated and placebo groups for males during the follow-up period Figure 6
Mean epg (± S.E.) (A. lumbricoides) in treated and placebo groups for males during the follow-up period. Treat-
ment group N = 103, Placebo group N = 90.
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dren necessitate systematic treatment of these children in
child health programmes [11]. Although nearly 20 years
have passed since the study by Holland et al [39] was con-
ducted, STHs still remain a significant problem in this
region and will most likely continue to do so in the future
without proper intervention.
Repeated four-monthly deworming treatments were effec-
tive in reducing prevalence and more importantly inten-
sity of A. lumbricoides infections with 1% and 11% of
individuals harbouring moderate infections at the end of
the study in the treatment and placebo groups respec-
tively. While shorter treatment intervals may be better at
reducing prevalence of Ascaris infections, in reality, two-
and three-monthly treatments may not be feasible and in
the long term, could promote drug resistance rendering
this broad spectrum anthelminthic less effective against
STH infections.
Overall, this study has clearly demonstrated the need to
incorporate preschool children into deworming pro-
grammes in endemic regions and to investigate innovative
ways of delivering cost effective deworming treatment to
this high risk age group.
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